The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지
DOI QR코드

DOI QR Code

Inhibition of Inducible Nitric Oxide Synthase Attenuates Monosodium Urate-induced Inflammation in Mice

  • Ju, Tae-Jin (Department of Physiology, Aging-associated Vascular Disease Research Center, College of Medicine, Yeungnam University) ;
  • Dan, Jin-Myoung (Department of Orthopedic Surgery, Gumi CHA University Hospital) ;
  • Cho, Young-Je (School of Food Science & Biotechnology, Food & Bio-Industry Research Institute, Kyungpook National University) ;
  • Park, So-Young (Department of Physiology, Aging-associated Vascular Disease Research Center, College of Medicine, Yeungnam University)
  • Received : 2011.09.30
  • Accepted : 2011.12.16
  • Published : 2011.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

The present study elucidated the effect of the selective inducible nitric oxide synthase (iNOS) inhibitor $N^6$-(1-iminoethyl)-L-lysine (L-NIL) on monosodium urate (MSU) crystal-induced inflammation and edema in mice feet. L-NIL (5 or 10 mg/kg/day) was administered intraperitoneally 4 h before injection of MSU (4 mg) into the soles of mice hindlimb feet. Twenty-four hours after MSU injection, foot thickness was increased by 160% and L-NIL pretreatment reduced food pad swelling in a dose dependent manner. Pretreatment of 10 mg/kg/day L-NIL significantly suppressed the foot pad swelling by MSU. Plasma level of nitric oxide (NO) metabolites and gene expression and protein level of iNOS in feet were increased by MSU, which was suppressed by L-NIL pretreatment. Similar pattern of change was observed in nitrotyrosine level. MSU increased the gene expression of tumor necrosis factor (TNF)-${\alpha}$ and interleukin (IL)-$1{\beta}$ and L-NIL pretreatment suppressed MSU-induced cytokines expression. The mRNA levels of superoxide dismutase and glutathione peroxidase1 were increased by MSU and L-NIL pretreatment normalized the gene expression. Phosphorylation of extracellular signal-regulated kinase 1/2 and p38 was increased by MSU, which was suppressed by L-NIL pretreatment. The mRNA levels of iNOS, TNF-${\alpha}$, and IL-$1{\beta}$ were increased by MSU in human dermal fibroblasts, C2C12 myoblasts, and human fetal osteoblasts in vitro, which was attenuated by L-NIL in a dose dependent manner. This study shows that L-NIL inhibits MSU-induced inflammation and edema in mice feet suggesting that iNOS might be involved in MSU-induced inflammation.

Keywords

References

  1. Keith MP, Gilliland WR. Updates in the management of gout. Am J Med. 2007;120:221-224. https://doi.org/10.1016/j.amjmed.2006.02.044
  2. Sabina EP, Rasool M, Mathew L, Ezilrani P, Indu H. 6-Shogaol inhibits monosodium urate crystal-induced inflammation--an in vivo and in vitro study. Food Chem Toxicol. 2010;48:229-235. https://doi.org/10.1016/j.fct.2009.10.005
  3. Eggebeen AT. Gout: an update. Am Fam Physician. 2007;76:801-808.
  4. Di Giovine FS, Malawista SE, Nuki G, Duff GW. Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1. J Immunol. 1987;138:3213-3218.
  5. Sabina EP, Chandal S, Rasool MK. Inhibition of monosodium urate crystal-induced inflammation by withaferin A. J Pharm Pharm Sci. 2008;11:46-55. https://doi.org/10.1002/jps.3080110119
  6. Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? J Clin Invest. 1997;100:2146-2152. https://doi.org/10.1172/JCI119750
  7. Noronha BT, Li JM, Wheatcroft SB, Shah AM, Kearney MT. Inducible nitric oxide synthase has divergent effects on vascular and metabolic function in obesity. Diabetes. 2005;54:1082-1089. https://doi.org/10.2337/diabetes.54.4.1082
  8. Tsuchiya K, Sakai H, Suzuki N, Iwashima F, Yoshimoto T, Shichiri M, Hirata Y. Chronic blockade of nitric oxide synthesis reduces adiposity and improves insulin resistance in high fat-induced obese mice. Endocrinology. 2007;148:4548-4556. https://doi.org/10.1210/en.2006-1371
  9. Kelm M. Nitric oxide metabolism and breakdown. Biochim Biophys Acta. 1999;1411:273-289. https://doi.org/10.1016/S0005-2728(99)00020-1
  10. Torres SH, De Sanctis JB, de L Briceno M, Hernandez N, Finol HJ. Inflammation and nitric oxide production in skeletal muscle of type 2 diabetic patients. J Endocrinol. 2004;181:419-427. https://doi.org/10.1677/joe.0.1810419
  11. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996;271:C1424-1437.
  12. Cha HN, Kim YW, Kim JY, Kim YD, Song IH, Min KN, Park SY. Lack of inducible nitric oxide synthase does not prevent aging-associated insulin resistance. Exp Gerontol. 2010;45:711-718. https://doi.org/10.1016/j.exger.2010.05.004
  13. Chen L, Hsieh MS, Ho HC, Liu YH, Chou DT, Tsai SH. Stimulation of inducible nitric oxide synthase by monosodium urate crystals in macrophages and expression of iNOS in gouty arthritis. Nitric Oxide. 2004;11:228-236. https://doi.org/10.1016/j.niox.2004.09.003
  14. Liu R, Liote F, Rose DM, Merz D, Terkeltaub R. Proline-rich tyrosine kinase 2 and Src kinase signaling transduce monosodium urate crystal-induced nitric oxide production and matrix metalloproteinase 3 expression in chondrocytes. Arthritis Rheum. 2004;50:247-258. https://doi.org/10.1002/art.11486
  15. Sabina EP, Rasool M. An in vivo and in vitro potential of Indian ayurvedic herbal formulation Triphala on experimental gouty arthritis in mice. Vascul Pharmacol. 2008;48:14-20. https://doi.org/10.1016/j.vph.2007.11.001
  16. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450-2461. https://doi.org/10.1056/NEJMoa050373
  17. Connor JR, Manning PT, Settle SL, Moore WM, Jerome GM, Webber RK, Tjoeng FS, Currie MG. Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur J Pharmacol. 1995;273:15-24. https://doi.org/10.1016/0014-2999(94)00672-T
  18. Chicoine LG, Tzeng E, Bryan R, Saenz S, Paffett ML, Jones J, Lyons CR, Resta TC, Nelin LD, Walker BR. Intratracheal adenoviral-mediated delivery of iNOS decreases pulmonary vasoconstrictor responses in rats. J Appl Physiol. 2004;97:1814-1822. https://doi.org/10.1152/japplphysiol.00193.2004
  19. Cha HN, Hong GR, Kim YW, Kim JY, Dan JM, Park SY. Deficiency of iNOS Does Not Prevent Isoproterenol-induced Cardiac Hypertrophy in Mice. Korean J Physiol Pharmacol. 2009;13:153-159. https://doi.org/10.4196/kjpp.2009.13.3.153
  20. van't Hof RJ, Hocking L, Wright PK, Ralston SH. Nitric oxide is a mediator of apoptosis in the rheumatoid joint. Rheumatology (Oxford). 2000;39:1004-1008. https://doi.org/10.1093/rheumatology/39.9.1004
  21. Maki-Petaja KM, Cheriyan J, Booth AD, Hall FC, Brown J, Wallace SM, Ashby MJ, McEniery CM, Wilkinson IB. Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction. Int J Cardiol. 2008;129:399-405. https://doi.org/10.1016/j.ijcard.2008.02.011
  22. Grabowski PS, Wright PK, Van't Hof RJ, Helfrich MH, Ohshima H, Ralston SH. Immunolocalization of inducible nitric oxide synthase in synovium and cartilage in rheumatoid arthritis and osteoarthritis. Br J Rheumatol. 1997;36:651-655. https://doi.org/10.1093/rheumatology/36.6.651
  23. Heale CE, Fahraeus-Van Ree GE, Rahman P, Richardson VJ. Progressive and concordant expression of PKC-eta and iNOS phenotypes in monocytes from patients with rheumatoid arthritis: association with disease severity. J Histochem Cytochem. 2007;55:495-503. https://doi.org/10.1369/jhc.6A7070.2007
  24. Borderie D, Hilliquin P, Hernvann A, Kahan A, Menkes CJ, Ekindjian OG. Nitric oxide synthase is expressed in the lymphomononuclear cells of synovial fluid in patients with rheumatoid arthritis. J Rheumatol. 1999;26:2083-2088.
  25. Vuolteenaho K, Moilanen T, Hamalainen M, Moilanen E. Regulation of nitric oxide production in osteoarthritic and rheumatoid cartilage. Role of endogenous IL-1 inhibitors. Scand J Rheumatol. 2003;32:19-24. https://doi.org/10.1080/03009740310000355
  26. Jarvinen K, Vuolteenaho K, Nieminen R, Moilanen T, Knowles RG, Moilanen E. Selective iNOS inhibitor 1400W enhances anti-catabolic IL-10 and reduces destructive MMP-10 in OA cartilage. Survey of the effects of 1400W on inflammatory mediators produced by OA cartilage as detected by protein antibody array. Clin Exp Rheumatol. 2008;26:275-282.
  27. Cuzzocrea S, Chatterjee PK, Mazzon E, McDonald MC, Dugo L, Di Paola R, Serraino I, Britti D, Caputi AP, Thiemermann C. Beneficial effects of GW274150, a novel, potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced arthritis. Eur J Pharmacol. 2002;453:119-129. https://doi.org/10.1016/S0014-2999(02)02338-5
  28. Jaramillo M, Naccache PH, Olivier M. Monosodium urate crystals synergize with IFN-gamma to generate macrophage nitric oxide: involvement of extracellular signal-regulated kinase 1/2 and NF-kappa B. J Immunol. 2004;172:5734-5742.
  29. Liu R, O'Connell M, Johnson K, Pritzker K, Mackman N, Terkeltaub R. Extracellular signal-regulated kinase 1/extra-cellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappaB transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells. Arthritis Rheum. 2000;43:1145-1155. https://doi.org/10.1002/1529-0131(200005)43:5<1145::AID-ANR25>3.0.CO;2-T
  30. Liu W, Kato M, Itoigawa M, Murakami H, Yajima M, Wu J, Ishikawa N, Nakashima I. Distinct involvement of NF-kappaB and p38 mitogen-activated protein kinase pathways in serum deprivation-mediated stimulation of inducible nitric oxide synthase and its inhibition by 4-hydroxynonenal. J Cell Biochem. 2001;83:271-280. https://doi.org/10.1002/jcb.1234
  31. Liu-Bryan R, Liote F. Monosodium urate and calcium pyrophosphate dihydrate (CPPD) crystals, inflammation, and cellular signaling. Joint Bone Spine. 2005;72:295-302. https://doi.org/10.1016/j.jbspin.2004.12.010
  32. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41:1287-1293. https://doi.org/10.1161/01.HYP.0000072820.07472.3B
  33. Inokuchi T, Ka T, Yamamoto A, Moriwaki Y, Takahashi S, Tsutsumi Z, Tamada D, Yamamoto T. Effects of ethanol on monosodium urate crystal-induced inflammation. Cytokine. 2008;42:198-204. https://doi.org/10.1016/j.cyto.2008.01.001
  34. McInnes IB, Leung BP, Field M, Wei XQ, Huang FP, Sturrock RD, Kinninmonth A, Weidner J, Mumford R, Liew FY. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients. J Exp Med. 1996;184:1519-1524. https://doi.org/10.1084/jem.184.4.1519
  35. di Giovine FS, Malawista SE, Thornton E, Duff GW. Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution. J Clin Invest. 1991;87:1375-1381. https://doi.org/10.1172/JCI115142
  36. Chapman PT, Yarwood H, Harrison AA, Stocker CJ, Jamar F, Gundel RH, Peters AM, Haskard DO. Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1. Arthritis Rheum. 1997;40:955-965. https://doi.org/10.1002/art.1780400525
  37. Rider TG, Jordan KM. The modern management of gout. Rheumatology (Oxford). 2010;49:5-14. https://doi.org/10.1093/rheumatology/kep306
  38. Chen YH, Hsieh SC, Chen WY, Li KJ, Wu CH, Wu PC, Tsai CY, Yu CL. Spontaneous resolution of acute gouty arthritis is associated with rapid induction of the anti-inflammatory factors TGF$\beta$1, IL-10 and soluble TNF receptors and the intracellular cytokine negative regulators CIS and SOCS3. Ann Rheum Dis. 2011;70:1655-1663. https://doi.org/10.1136/ard.2010.145821
  39. Ghio AJ, Kennedy TP, Rao G, Cooke CL, Miller MJ, Hoidal JR. Complexation of iron cation by sodium urate crystals and gouty inflammation. Arch Biochem Biophys. 1994;313:215-221. https://doi.org/10.1006/abbi.1994.1379
  40. Facchini FS. Near-iron deficiency-induced remission of gouty arthritis. Rheumatology (Oxford). 2003;42:1550-1555. https://doi.org/10.1093/rheumatology/keg402

Cited by

  1. [Ru(bpy) 2 (NO)SO 3 ](PF 6 ), a Nitric Oxide Donating Ruthenium Complex, Reduces Gout Arthritis in Mice vol.10, pp.None, 2011, https://doi.org/10.3389/fphar.2019.00229
  2. Involvement of inflammasome activation via elevation of uric acid level in nociception in a mouse model of muscle pain vol.15, pp.None, 2011, https://doi.org/10.1177/1744806919858797
  3. Integrated Strategy From In Vitro, In Situ, In Vivo to In Silico for Predicting Active Constituents and Exploring Molecular Mechanisms of Tongfengding Capsule for Treating Gout by Inhibiting Inflammat vol.12, pp.None, 2011, https://doi.org/10.3389/fphar.2021.759157